Author/Editor		Kogoj, A
Title		Actual treatment of cognitive symptoms of Alzheimer's disease and future perspectives
Type		članek
Source		Neurol Croat
Vol. and No.		Letnik 51, št. 3-4
Publication year		2002
Volume		str. 199-211
Language		eng
Abstract		Presently, cholinesterase inhibitors represent the drugs of choice for the treatment of cognitive deficite in Alzheimer's disease. Tacrine was the first agent approved specifically for treating the cognitive symptoms of Alzheimer's disease. While donepezil, rivastigmine and galantamine were later approved, development of some cholinesterase inhibitors was stopped. Searching for more effective cholinergic agonists (muscarinic and nicotinic agonists), other neurotransmitter based drugs and non-neurotransmitter based drugs are being developed. New drugs will not provide only symptomatic therapy. Drugs that affect processing of the amyloid precursor protein, and tau accumulation, drugs that modulate microglial activation, anti-oxidants, gene therapy, transplant strategies and others may alter the disease process.
Descriptors		ALZHEIMER'S DISEASE COGNITION DISORDERS CHOLINESTERASE INHIBITORS TACRINE GALANTHAMINE CHOLINERGIC AGONISTS MEMANTINE VITAMIN E